Trial of Tirzepatide for the Treatment of Cannabis Use Disorder

The purpose of this randomized, double-blind, placebo-controlled, multi-site clinical trial is to evaluate the safety and efficacy of tirzepatide in a sample of 100 patients diagnosed with moderate or severe CUD by DSM-5 criteria.

Inclusion Criteria: * Between 18 and 70 years of age * Meets DSM-5 criteria for moderate or severe CUD * Interested in treatment for cannabis use disorder * Able to understand the study procedures and written informed consent in English * Willing to comply with all study procedures and medication instructions * If female, is not pregnant, and agrees to use acceptable birth control methods Exclusion Criteria: * Body Mass Index (BMI) ≤ 23 kg/m² * Presence of a medical or psychiatric disorder that contraindicates participation in the study * Substance use disorder other than tobacco or mild alcohol-use disorder * Known allergy or hypersensitivity to Tirzepatide, any GLP-1 or GIP receptor agonist, or any of the excipients in the product * Current or recent (past 30 days) use of GLP-1 receptor agonists or other weight-loss drug * Current or recent (past 6 months) enrollment in substance use disorder treatment * Current or planned pregnancy and breastfeeding * Living or medical situation that would interfere with adherence to the study protocol